26/07/2017 ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
(WorldNews Belgium)

ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP GHENT, Belgium, 26 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for caplacizumab, the Company`s first-in-class anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). The FDA`s Fast Track programme is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. Drugs that receive this designation are eligible for more frequent...